4D Molecular Therapeutics (FDMT) Accumulated Depreciation & Amortization (2019 - 2025)
Historic Accumulated Depreciation & Amortization for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $20.1 million.
- 4D Molecular Therapeutics' Accumulated Depreciation & Amortization rose 2952.23% to $20.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 2952.23%. This contributed to the annual value of $16.6 million for FY2024, which is 3899.6% up from last year.
- Latest data reveals that 4D Molecular Therapeutics reported Accumulated Depreciation & Amortization of $20.1 million as of Q3 2025, which was up 2952.23% from $18.8 million recorded in Q2 2025.
- 4D Molecular Therapeutics' Accumulated Depreciation & Amortization's 5-year high stood at $20.1 million during Q3 2025, with a 5-year trough of $4.2 million in Q1 2021.
- For the 5-year period, 4D Molecular Therapeutics' Accumulated Depreciation & Amortization averaged around $10.7 million, with its median value being $9.8 million (2023).
- Per our database at Business Quant, 4D Molecular Therapeutics' Accumulated Depreciation & Amortization soared by 6131.96% in 2023 and then soared by 2952.23% in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Accumulated Depreciation & Amortization stood at $5.3 million in 2021, then surged by 45.13% to $7.7 million in 2022, then soared by 54.4% to $11.9 million in 2023, then surged by 39.0% to $16.6 million in 2024, then rose by 20.97% to $20.1 million in 2025.
- Its Accumulated Depreciation & Amortization was $20.1 million in Q3 2025, compared to $18.8 million in Q2 2025 and $17.6 million in Q1 2025.